Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Synergy and antagonism in the integration of BCR and CD40 signals that control B-cell proliferation

View through CrossRef
ABSTRACT In response to infection or vaccination, a successful antibody response must enrich high-affinity antigen-reactive B-cells through positive selection, but eliminate auto-reactive B-cells through negative selection. B-cells receive signals from the B-cell receptor (BCR) which binds the antigen, and the CD40 receptor which is stimulated by neighboring T-cells that also recognize the antigen. How BCR and CD40 signaling are integrated quantitatively to jointly determine B-cell fate decision and proliferation remains unclear. To investigate this, we developed a differential-equations-based model of the BCR and CD40 signaling networks activating NFκB. Our model accurately recapitulates the NFκB dynamics of B-cells stimulated through their BCR and CD40 receptors, correctly predicting that costimulation induces more NFκB activity. However, when linking it to established cell fate decision models of cell survival and cell cycle control, it predicted potentiated population expansion that was not observed experimentally. We found that this discrepancy was due to a time-dependent functional antagonism exacerbated by BCR-induced caspase activity that can trigger apoptosis in founder cells, unless NFκB-induced survival gene expression protects B-cells in time. Guided by model predictions, sequential co-stimulation experiments revealed how the temporal dynamics of BCR and CD40 signaling control the fate decision between negative and positive selection of B-cell clonal expansion. Our quantitative findings highlight a complex non-monotonic integration of BCR and CD40 signals that is controlled by a balance between NFκB and cell-death pathways, and suggest a mechanism for regulating the stringency of B-cell selection during an antibody response. Highlights CD40 and BCR signaling in B-cells synergize to potentiate NFκB cRel activation BCR-apoptotic signaling may enhance or antagonize CD40-driven proliferation BCR-induced apoptosis may be rescued by CD40 within a temporal window A mathematical model reveals regulators of the dose-dependent selection stringency
Title: Synergy and antagonism in the integration of BCR and CD40 signals that control B-cell proliferation
Description:
ABSTRACT In response to infection or vaccination, a successful antibody response must enrich high-affinity antigen-reactive B-cells through positive selection, but eliminate auto-reactive B-cells through negative selection.
B-cells receive signals from the B-cell receptor (BCR) which binds the antigen, and the CD40 receptor which is stimulated by neighboring T-cells that also recognize the antigen.
How BCR and CD40 signaling are integrated quantitatively to jointly determine B-cell fate decision and proliferation remains unclear.
To investigate this, we developed a differential-equations-based model of the BCR and CD40 signaling networks activating NFκB.
Our model accurately recapitulates the NFκB dynamics of B-cells stimulated through their BCR and CD40 receptors, correctly predicting that costimulation induces more NFκB activity.
However, when linking it to established cell fate decision models of cell survival and cell cycle control, it predicted potentiated population expansion that was not observed experimentally.
We found that this discrepancy was due to a time-dependent functional antagonism exacerbated by BCR-induced caspase activity that can trigger apoptosis in founder cells, unless NFκB-induced survival gene expression protects B-cells in time.
Guided by model predictions, sequential co-stimulation experiments revealed how the temporal dynamics of BCR and CD40 signaling control the fate decision between negative and positive selection of B-cell clonal expansion.
Our quantitative findings highlight a complex non-monotonic integration of BCR and CD40 signals that is controlled by a balance between NFκB and cell-death pathways, and suggest a mechanism for regulating the stringency of B-cell selection during an antibody response.
Highlights CD40 and BCR signaling in B-cells synergize to potentiate NFκB cRel activation BCR-apoptotic signaling may enhance or antagonize CD40-driven proliferation BCR-induced apoptosis may be rescued by CD40 within a temporal window A mathematical model reveals regulators of the dose-dependent selection stringency.

Related Results

Blood-Borne, but Not Endothelial CD40 Promotes Experimental Lung Metastasis.
Blood-Borne, but Not Endothelial CD40 Promotes Experimental Lung Metastasis.
Abstract During experimental lung metastasis, procoagulant tumor cells adhere to the microvascular endothelium and activate coagulation, which leads to thrombin gene...
PARP Inhibition Sensitize BCR-ABL1 Positive Cel
PARP Inhibition Sensitize BCR-ABL1 Positive Cel
Introduction: BCR-ABL1 play a key role in the development of chronic myelogenous leukemia and a part of Ph1 positive acute lymphoblastic leukemia (ALL). BCR-ABL1 fun...
TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL
TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL
Chronic myeloid leukemia (CML) is a hematopoietic malignancy caused by the BCR-ABL fusion gene. Although tyrosine kinase inhibitors (TKIs) targeting the oncoprotein BCR-ABL have dr...
Cd40 Activation as Potential Tool in Malignant Neoplasms
Cd40 Activation as Potential Tool in Malignant Neoplasms
Background CD40, a cell surface molecule, is expressed on B-cell malignancies and many different solid tumors. It is capable of mediating diverse biological phe...
CD40 preferentially costimulates activation of CD4+ T lymphocytes.
CD40 preferentially costimulates activation of CD4+ T lymphocytes.
Abstract CD40 is a membrane differentiation antigen constitutively expressed on B cells that induces B cell growth and Ig synthesis after ligation with anti-CD40 ...
Abstract 5049: Prediction of pharmacokinetics and receptor occupancy of a bispecific antibody against CD40 and PD-L1
Abstract 5049: Prediction of pharmacokinetics and receptor occupancy of a bispecific antibody against CD40 and PD-L1
Abstract Background: Currently bispecific monoclonal antibodies gain traction in pharmacology as a way to simultaneously target different surface molecules on immune...
CD40-CD40 ligand
CD40-CD40 ligand
Abstract CD40 is a cell surface receptor that belongs to the tumor necrosis factor-R (TNF-R) family, and that was first identified and functionally characterized on ...
Agonistic CD40 Antibodies in Cancer Treatment
Agonistic CD40 Antibodies in Cancer Treatment
CD40 is expressed on a variety of antigen-presenting cells. Stimulation of CD40 results in inflammation by upregulation of other costimulatory molecules, increased antigen presenta...

Back to Top